vs
ANI PHARMACEUTICALS INC（ANIP）とEZCORP INC（EZPW）の財務データ比較。上の社名をクリックして会社を切り替えられます
EZCORP INCの直近四半期売上が大きい（$382.0M vs $247.1M、ANI PHARMACEUTICALS INCの約1.5倍）。EZCORP INCの純利益率が高く（11.6% vs 11.1%、差は0.5%）。ANI PHARMACEUTICALS INCの前年同期比売上増加率が高い（29.6% vs 19.3%）。EZCORP INCの直近四半期フリーキャッシュフローが多い（$31.7M vs $29.1M）。過去8四半期でANI PHARMACEUTICALS INCの売上複合成長率が高い（34.1% vs 15.6%）
ANIファーマシューティカルズは米国に本社を置く特殊製薬会社で、後発医薬品とブランド処方薬の研究開発・製造・販売を行っています。主力製品分野は皮膚科、腫瘍、中枢神経系治療、感染症対策で、主に米国内の医療機関、調剤薬局、患者を対象としています。
EZCORPはアメリカ合衆国テキサス州オースティンを本拠とする質屋運営企業です。アメリカ全土およびラテンアメリカで事業を展開しており、Cash America Internationalに次いでアメリカで2番目に規模の大きい質屋運営業者で、ナスダックに上場しています。
ANIP vs EZPW — 直接比較
損益計算書 — Q4 FY2025 vs Q1 FY2026
| 指標 | | |
|---|---|---|
| 売上 | $247.1M | $382.0M |
| 純利益 | $27.5M | $44.3M |
| 粗利率 | — | 58.4% |
| 営業利益率 | 14.1% | 15.9% |
| 純利益率 | 11.1% | 11.6% |
| 売上前年比 | 29.6% | 19.3% |
| 純利益前年比 | 367.5% | 42.8% |
| EPS（希薄化後） | $1.14 | $0.55 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $247.1M | $382.0M | ||
| Q3 25 | $227.8M | $336.8M | ||
| Q2 25 | $211.4M | $311.0M | ||
| Q1 25 | $197.1M | $306.3M | ||
| Q4 24 | $190.6M | $320.2M | ||
| Q3 24 | $148.3M | $294.6M | ||
| Q2 24 | $138.0M | $281.4M | ||
| Q1 24 | $137.4M | $285.6M |
| Q4 25 | $27.5M | $44.3M | ||
| Q3 25 | $26.6M | $26.7M | ||
| Q2 25 | $8.5M | $26.5M | ||
| Q1 25 | $15.7M | $25.4M | ||
| Q4 24 | $-10.3M | $31.0M | ||
| Q3 24 | $-24.2M | $15.2M | ||
| Q2 24 | $-2.3M | $17.9M | ||
| Q1 24 | $18.2M | $21.5M |
| Q4 25 | — | 58.4% | ||
| Q3 25 | — | 59.0% | ||
| Q2 25 | — | 59.1% | ||
| Q1 25 | — | 58.3% | ||
| Q4 24 | — | 57.9% | ||
| Q3 24 | — | 59.5% | ||
| Q2 24 | — | 59.2% | ||
| Q1 24 | — | 58.7% |
| Q4 25 | 14.1% | 15.9% | ||
| Q3 25 | 15.9% | 11.0% | ||
| Q2 25 | 6.6% | 11.6% | ||
| Q1 25 | 13.3% | 11.2% | ||
| Q4 24 | -2.3% | 13.1% | ||
| Q3 24 | -13.8% | 8.8% | ||
| Q2 24 | 3.7% | 7.9% | ||
| Q1 24 | 14.8% | 9.6% |
| Q4 25 | 11.1% | 11.6% | ||
| Q3 25 | 11.7% | 7.9% | ||
| Q2 25 | 4.0% | 8.5% | ||
| Q1 25 | 8.0% | 8.3% | ||
| Q4 24 | -5.4% | 9.7% | ||
| Q3 24 | -16.3% | 5.2% | ||
| Q2 24 | -1.7% | 6.4% | ||
| Q1 24 | 13.2% | 7.5% |
| Q4 25 | $1.14 | $0.55 | ||
| Q3 25 | $1.13 | $0.35 | ||
| Q2 25 | $0.36 | $0.34 | ||
| Q1 25 | $0.69 | $0.33 | ||
| Q4 24 | $-0.45 | $0.40 | ||
| Q3 24 | $-1.27 | $0.20 | ||
| Q2 24 | $-0.14 | $0.25 | ||
| Q1 24 | $0.82 | $0.29 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $285.6M | $465.9M |
| 総負債低いほど良い | — | $518.6M |
| 株主資本純資産 | $540.7M | $1.1B |
| 総資産 | $1.4B | $2.0B |
| 負債/資本比率低いほどレバレッジが低い | — | 0.48× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $285.6M | $465.9M | ||
| Q3 25 | $262.6M | $469.5M | ||
| Q2 25 | $217.8M | $472.1M | ||
| Q1 25 | $149.8M | $505.2M | ||
| Q4 24 | $144.9M | $174.5M | ||
| Q3 24 | $145.0M | $170.5M | ||
| Q2 24 | $240.1M | $218.0M | ||
| Q1 24 | $228.6M | $229.1M |
| Q4 25 | — | $518.6M | ||
| Q3 25 | — | $518.1M | ||
| Q2 25 | — | $517.6M | ||
| Q1 25 | — | $620.5M | ||
| Q4 24 | — | $327.7M | ||
| Q3 24 | — | $327.3M | ||
| Q2 24 | — | $361.3M | ||
| Q1 24 | — | $360.9M |
| Q4 25 | $540.7M | $1.1B | ||
| Q3 25 | $505.8M | $1.0B | ||
| Q2 25 | $436.8M | $990.1M | ||
| Q1 25 | $418.6M | $851.6M | ||
| Q4 24 | $403.7M | $823.9M | ||
| Q3 24 | $405.9M | $804.6M | ||
| Q2 24 | $455.8M | $801.5M | ||
| Q1 24 | $452.0M | $800.4M |
| Q4 25 | $1.4B | $2.0B | ||
| Q3 25 | $1.4B | $2.0B | ||
| Q2 25 | $1.3B | $1.9B | ||
| Q1 25 | $1.3B | $1.8B | ||
| Q4 24 | $1.3B | $1.5B | ||
| Q3 24 | $1.3B | $1.5B | ||
| Q2 24 | $920.8M | $1.5B | ||
| Q1 24 | $914.5M | $1.5B |
| Q4 25 | — | 0.48× | ||
| Q3 25 | — | 0.51× | ||
| Q2 25 | — | 0.52× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.40× | ||
| Q3 24 | — | 0.41× | ||
| Q2 24 | — | 0.45× | ||
| Q1 24 | — | 0.45× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $30.4M | $39.1M |
| フリーキャッシュフロー営業CF - 設備投資 | $29.1M | $31.7M |
| FCFマージンFCF / 売上 | 11.8% | 8.3% |
| 設備投資強度設備投資 / 売上 | 0.5% | 2.0% |
| キャッシュ転換率営業CF / 純利益 | 1.10× | 0.88× |
| 直近12ヶ月FCF直近4四半期 | $171.4M | $121.7M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $30.4M | $39.1M | ||
| Q3 25 | $44.1M | $51.3M | ||
| Q2 25 | $75.8M | $34.8M | ||
| Q1 25 | $35.0M | $36.9M | ||
| Q4 24 | $15.9M | $26.0M | ||
| Q3 24 | $12.5M | $43.3M | ||
| Q2 24 | $17.4M | $33.7M | ||
| Q1 24 | $18.3M | $15.1M |
| Q4 25 | $29.1M | $31.7M | ||
| Q3 25 | $38.0M | $35.7M | ||
| Q2 25 | $71.8M | $25.7M | ||
| Q1 25 | $32.5M | $28.6M | ||
| Q4 24 | $13.5M | $20.4M | ||
| Q3 24 | $7.7M | $24.4M | ||
| Q2 24 | $13.0M | $30.5M | ||
| Q1 24 | $13.7M | $8.6M |
| Q4 25 | 11.8% | 8.3% | ||
| Q3 25 | 16.7% | 10.6% | ||
| Q2 25 | 34.0% | 8.3% | ||
| Q1 25 | 16.5% | 9.3% | ||
| Q4 24 | 7.1% | 6.4% | ||
| Q3 24 | 5.2% | 8.3% | ||
| Q2 24 | 9.4% | 10.8% | ||
| Q1 24 | 10.0% | 3.0% |
| Q4 25 | 0.5% | 2.0% | ||
| Q3 25 | 2.7% | 4.6% | ||
| Q2 25 | 1.9% | 2.9% | ||
| Q1 25 | 1.3% | 2.7% | ||
| Q4 24 | 1.3% | 1.8% | ||
| Q3 24 | 3.2% | 6.4% | ||
| Q2 24 | 3.2% | 1.1% | ||
| Q1 24 | 3.3% | 2.3% |
| Q4 25 | 1.10× | 0.88× | ||
| Q3 25 | 1.66× | 1.92× | ||
| Q2 25 | 8.87× | 1.31× | ||
| Q1 25 | 2.23× | 1.45× | ||
| Q4 24 | — | 0.84× | ||
| Q3 24 | — | 2.85× | ||
| Q2 24 | — | 1.88× | ||
| Q1 24 | 1.00× | 0.70× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
EZPW
| Merchandise | $210.1M | 55% |
| Pawn Service | $131.9M | 35% |
| Jewelry Scrap | $39.9M | 10% |
